Do analysts prefer IMA or GTBP?

ImageneBio currently has a consensus target price of $28.00, indicating a potential upside of 605.29%. Given ImageneBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe ImageneBio is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMA or GTBP more profitable?

ImageneBio's return on equity of -38.99% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% GT Biopharma N/A -213.16% -150.61%

Does the media favor IMA or GTBP?

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. ImageneBio's average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATNM or GTBP more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% GT Biopharma N/A -213.16% -150.61%

Does the media favor ATNM or GTBP?

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat Actinium Pharmaceuticals' score of -0.13 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GTBP or KLRS?

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 715.22%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher valuation & earnings, GTBP or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$147.50 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is GTBP or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media prefer GTBP or KLRS?

In the previous week, GT Biopharma had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for GT Biopharma and 1 mentions for Kalaris Therapeutics. GT Biopharma's average media sentiment score of 0.00 beat Kalaris Therapeutics' score of -0.35 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ANVS or GTBP?

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 1,236.30%. Given Annovis Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Annovis Bio is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ANVS or GTBP?

Annovis Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A GT Biopharma N/A N/A -$28.35M -$147.50 N/A

Is ANVS or GTBP more profitable?

GT Biopharma's return on equity of -213.16% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% GT Biopharma N/A -213.16% -150.61%

Does the media prefer ANVS or GTBP?

In the previous week, Annovis Bio had 8 more articles in the media than GT Biopharma. MarketBeat recorded 10 mentions for Annovis Bio and 2 mentions for GT Biopharma. Annovis Bio's average media sentiment score of 0.56 beat GT Biopharma's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GTBP or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is GTBP or INMB more profitable?

INmune Bio's return on equity of -82.87% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% INmune Bio N/A -82.87% -62.23%

Does the media refer more to GTBP or INMB?

In the previous week, INmune Bio had 4 more articles in the media than GT Biopharma. MarketBeat recorded 6 mentions for INmune Bio and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat INmune Bio's score of -0.13 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

GT Biopharma (GTBP) Competitors

$4.32 -0.10 (-2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$4.43 +0.11 (+2.64%)

As of 07:57 PM Eastern

Compare

GTBP vs. IMA, ATNM, KLRS, ANVS, and INMB

Should you buy GT Biopharma stock or one of its competitors? GT Biopharma's main competitors and comparable companies include ImageneBio (IMA), Actinium Pharmaceuticals (ATNM), Kalaris Therapeutics (KLRS), Annovis Bio (ANVS), and INmune Bio (INMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GT Biopharma compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 1.1% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. ImageneBio's average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImageneBio currently has a consensus target price of $28.00, indicating a potential upside of 605.29%. Given ImageneBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe ImageneBio is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	56.32	-$45.35M	-$4.58	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

ImageneBio has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

ImageneBio's return on equity of -38.99% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
GT Biopharma	N/A	-213.16%	-150.61%

Summary

ImageneBio beats GT Biopharma on 9 of the 11 factors compared between the two stocks.

How does GT Biopharma compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Actinium Pharmaceuticals' return on equity of -100.85% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
GT Biopharma	N/A	-213.16%	-150.61%

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for Actinium Pharmaceuticals and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat Actinium Pharmaceuticals' score of -0.13 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 0.9% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GT Biopharma has lower revenue, but higher earnings than Actinium Pharmaceuticals. GT Biopharma is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	1.38	-$48.82M	$0.36	4.28
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

Actinium Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 224.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Actinium Pharmaceuticals beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to Kalaris Therapeutics?

GT Biopharma (NASDAQ:GTBP) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

GT Biopharma has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Kalaris Therapeutics' return on equity of -71.71% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 715.22%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, GT Biopharma had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for GT Biopharma and 1 mentions for Kalaris Therapeutics. GT Biopharma's average media sentiment score of 0.00 beat Kalaris Therapeutics' score of -0.35 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.1% of GT Biopharma shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kalaris Therapeutics beats GT Biopharma on 8 of the 12 factors compared between the two stocks.

How does GT Biopharma compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by company insiders. Comparatively, 1.1% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Annovis Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A

Annovis Bio has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

GT Biopharma's return on equity of -213.16% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
GT Biopharma	N/A	-213.16%	-150.61%

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 1,236.30%. Given Annovis Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Annovis Bio is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Annovis Bio had 8 more articles in the media than GT Biopharma. MarketBeat recorded 10 mentions for Annovis Bio and 2 mentions for GT Biopharma. Annovis Bio's average media sentiment score of 0.56 beat GT Biopharma's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Annovis Bio beats GT Biopharma on 9 of the 12 factors compared between the two stocks.

How does GT Biopharma compare to INmune Bio?

GT Biopharma (NASDAQ:GTBP) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

GT Biopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, INmune Bio had 4 more articles in the media than GT Biopharma. MarketBeat recorded 6 mentions for INmune Bio and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 0.00 beat INmune Bio's score of -0.13 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 1.1% of GT Biopharma shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

GT Biopharma has higher earnings, but lower revenue than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$147.50	N/A
INmune Bio	$50K	631.90	-$45.93M	-$0.60	N/A

INmune Bio's return on equity of -82.87% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
INmune Bio	N/A	-82.87%	-62.23%

Summary

INmune Bio beats GT Biopharma on 10 of the 12 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.98M	$4.21B	$7.93B	$12.28B
Dividend Yield	N/A	3.62%	2.46%	4.40%
P/E Ratio	N/A	33.12	35.60	29.15
Price / Sales	N/A	17.54	9.09	5.94
Price / Cash	12.94	23.45	21.38	22.89
Price / Book	0.76	4.55	4.78	4.02
Net Income	-$28.35M	-$22.13M	$3.50B	$381.74M
7 Day Performance	-15.79%	1.96%	1.75%	0.53%
1 Month Performance	-35.33%	-6.54%	-3.59%	-5.67%
1 Year Performance	-72.11%	6.27%	4.54%	-4.40%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.2218 of 5 stars	$4.32 -2.3%	N/A	-71.5%	$9.98M	N/A	N/A	1	News Coverage Upcoming Earnings Gap Down High Trading Volume
IMA ImageneBio	1.5271 of 5 stars	$4.02 -0.7%	$28.00 +596.5%	-50.6%	$45.63M	$800K	N/A	18	News Coverage Earnings Report
ATNM Actinium Pharmaceuticals	1.8762 of 5 stars	$1.42 +1.4%	$5.00 +252.1%	+13.5%	$44.65M	$35.09M	N/A	25
KLRS Kalaris Therapeutics	3.0609 of 5 stars	$1.86 +3.3%	$18.75 +908.1%	-49.1%	$44.29M	N/A	N/A	20	News Coverage Analyst Downgrade
ANVS Annovis Bio	3.6627 of 5 stars	$1.01 +5.0%	$12.00 +1,094.0%	-59.1%	$42.89M	N/A	N/A	7	News Coverage Upcoming Earnings Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 11/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. IMA, ATNM, KLRS, ANVS, and INMB

How does GT Biopharma compare to ImageneBio?

Summary

How does GT Biopharma compare to Actinium Pharmaceuticals?

Summary

How does GT Biopharma compare to Kalaris Therapeutics?

Summary

How does GT Biopharma compare to Annovis Bio?

Summary

How does GT Biopharma compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. IMA, ATNM, KLRS, ANVS, and INMB

How does GT Biopharma compare to ImageneBio?

Do insiders & institutionals believe in IMA or GTBP?

Does the media favor IMA or GTBP?

Do analysts prefer IMA or GTBP?

Which has higher earnings and valuation, IMA or GTBP?

Which has more risk & volatility, IMA or GTBP?

Is IMA or GTBP more profitable?

Summary

How does GT Biopharma compare to Actinium Pharmaceuticals?

Is ATNM or GTBP more profitable?

Does the media favor ATNM or GTBP?

Do insiders and institutionals believe in ATNM or GTBP?

Which has stronger valuation and earnings, ATNM or GTBP?

Which has more volatility & risk, ATNM or GTBP?

Do analysts prefer ATNM or GTBP?

Summary

How does GT Biopharma compare to Kalaris Therapeutics?

Which has higher valuation & earnings, GTBP or KLRS?

Which has more risk and volatility, GTBP or KLRS?

Is GTBP or KLRS more profitable?

Do analysts prefer GTBP or KLRS?

Does the media prefer GTBP or KLRS?

Do institutionals & insiders have more ownership in GTBP or KLRS?

Summary

How does GT Biopharma compare to Annovis Bio?

Do insiders & institutionals have more ownership in ANVS or GTBP?

Which has stronger valuation & earnings, ANVS or GTBP?

Which has more risk and volatility, ANVS or GTBP?

Is ANVS or GTBP more profitable?

Do analysts recommend ANVS or GTBP?

Does the media prefer ANVS or GTBP?

Summary

How does GT Biopharma compare to INmune Bio?

Which has more volatility and risk, GTBP or INMB?

Does the media refer more to GTBP or INMB?

Do insiders and institutionals have more ownership in GTBP or INMB?

Do analysts recommend GTBP or INMB?

Which has stronger valuation & earnings, GTBP or INMB?

Is GTBP or INMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools